Dr. Lal PathLabs Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Dr. Lal PathLabs Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 6.1 times. Higher than 93% of Healthcare companies in India.
- Cash Locked Ratio: Money owed to suppliers is larger than money owed by customers plus stock: ₹3 per ₹100 of sales comes from others' credit, against ₹3 from others' credit three years earlier. Less money tied up than 92% of Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹76 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 86% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹129Over the last 3 years, every ₹100 of reported profit came with ₹129 of operating cash.
Higher than 60% of Healthcare companies in India.
Self-Funding Ratio
6.1×Over the last 3 years its own operating cash covered its investment spending (capex) 6.1 times.
Higher than 93% of Healthcare companies in India.
Cash Locked Ratio
−₹3Money owed to suppliers is larger than money owed by customers plus stock: ₹3 per ₹100 of sales comes from others' credit, against ₹3 from others' credit three years earlier.
Less money tied up than 92% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 83% of Healthcare companies in India.
Growth Efficiency Ratio
₹36Sales grew 37% in 3 years; of every extra ₹100 of sales, ₹36 became extra profit.
Higher than 83% of Healthcare companies in India.
Asset Productivity Ratio
+37% / +32%In 3 years sales changed by +37% while total assets changed by +32%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
11.9×Debt due within a year is covered 11.9 times by its yearly operating cash.
Higher than 78% of Healthcare companies in India.
Cash Cushion Ratio
+4%Cash, after subtracting all debt, equals 4% of its market value (net cash).
Higher than 77% of Healthcare companies in India.
Tangible Assets Ratio
76%Of every ₹100 the company owns, ₹76 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 86% of Healthcare companies in India.
Tangible Net Worth Ratio
70%Of every ₹100 of net worth, ₹70 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 79% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Dr. Lal PathLabs Limited owes ₹0.19 for every ₹1 it owns. Net profit rose 4% in the year to Mar 2026, and grew 28% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
56.7Investors pay ₹56.7 for every ₹1 of Dr. Lal PathLabs Limited's yearly profit, higher than 76% of Healthcare companies in India.
P/B ratio
12.25The share price is 12.25 times Dr. Lal PathLabs Limited's book value per share, higher than 88% of Healthcare companies in India.
Market cap
₹30,737 CrThe total market value of all of Dr. Lal PathLabs Limited's shares at today's price (share price × number of shares), larger than 83% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹2,508 CrWhat Dr. Lal PathLabs Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹150.00Net worth divided by the number of shares. The share price of ₹1,838 is 12.3 times this, which is the P/B above.
Return on equity (ROE)
21.6%Dr. Lal PathLabs Limited earned 21.6% on its shareholders' money over the last year, higher than 84% of Healthcare companies in India.
Owes vs Owns
0.19×Dr. Lal PathLabs Limited owes ₹0.19 for every ₹1 it owns (low), lower than 83% of Healthcare companies in India.
Dividend yield
1.03%Dr. Lal PathLabs Limited pays 1.03% of its share price as dividends a year, higher than 81% of dividend-paying Healthcare companies in India.
Revenue growth
+12%Revenue rose 12% in the year to Mar 2026, and grew 11% a year on average over 3 years.
Profit growth
+4%Net profit rose 4% in the year to Mar 2026, and grew 28% a year on average over 3 years.
Profit margin
18.3%Dr. Lal PathLabs Limited keeps ₹18 of every ₹100 of revenue as net profit.
Cash quality
1.3×Cash from Dr. Lal PathLabs Limited's business was 1.3× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
45.0×Dr. Lal PathLabs Limited's operating profit covered its interest costs 45.0 times in the year to Mar 2026.
Cash vs debt
Net cashDr. Lal PathLabs Limited held ₹1,132 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Dr. Lal PathLabs Limited's P/E ratio?
Investors pay ₹56.7 for every ₹1 of Dr. Lal PathLabs Limited's yearly profit, higher than 76% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Dr. Lal PathLabs Limited: ₹30,737 Cr ÷ ₹2,508 Cr (31 Mar 2026) = 12.3.
What is Dr. Lal PathLabs Limited's return on equity?
Dr. Lal PathLabs Limited earned 21.6% on its shareholders' money over the last year, higher than 84% of Healthcare companies in India.
How much does Dr. Lal PathLabs Limited owe compared with what it owns?
Dr. Lal PathLabs Limited owes ₹0.19 for every ₹1 it owns (low), lower than 83% of Healthcare companies in India.
Does Dr. Lal PathLabs Limited pay a dividend?
Yes. Dr. Lal PathLabs Limited pays 1.03% of its share price as dividends a year, higher than 81% of dividend-paying Healthcare companies in India.
Is Dr. Lal PathLabs Limited's revenue growing?
Revenue rose 12% in the year to Mar 2026, and grew 11% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.